Tag: drug development

The Terrible, Horrible, No Good, Very Bad Pharma Day*

A challenge You are passionate about providing an intervention (drug or device) to a group of patients who can’t access the current options due to availability or pricing. You could could go the philanthropic route to pay for the interventions. You could work towards regulation to apply downward pressure on pricing. No matter what, you have to

Read More

Blood: Underappreciated Resource in the Health/Disease?

Alternative title: Pitching a VC on Disruption of Blood Testing You may have seen some recent editorials about the necessary frequency of blood tests for healthy individuals, many of them prompted by a series of tweets from Mark Cuban: Although there are certainly potential dangers in expecting any and all test results to be immediately

Read More

Case Study: When does “technology” turn into medical device

This semester I’ve embarked on an adventure to co-teach a class in the University of Wisconsin-Madison Masters in Biotechnology program. What sold me on the experience was the majority of my responsibility is interacting with second year students on their final major project (essentially their thesis). That said, I will give one lecture, which will be “health

Read More

What is the optimal biotech burn rate?

Ethan Perlstein, founder of Perlstein Lab, asked a question on Twitter and got some great answers from David Grainger, partner at Index Ventures and Katrine Bosley, CEO of Editas Medicine. (You can read the whole thread by clicking through.) @LifeSciVC @sciencescanner @ksbosley @scientre what's the burn rate distribution of biotech NewCos in for the first year of

Read More

US Biosimilars Pathway – A Step Closer to Reality

Today Sandoz announced that their Biologics License Application for filgrastim was accepted by the FDA. This news is significant in part because Zarzio (the brand name for this new product) is the first product to use the 351(k) pathway for biosimilars in the US (rather than the traditional 351(a) BLA). In contrast, there are a

Read More

Silos in Drug Development

I was in Chicago last month for the American Society of Clinical Oncology (ASCO) annual meeting where as you would expect the topic of conversation was cancer at every turn. While it is generally easy to get wrapped up in these conversations, this year was different. Just a couple of weeks before the meeting, I

Read More

Drug Development & the User Experience

What is Tech UX? I was recently at a local event for entrepreneurs (thanks Capital Entrepreneurs) and struck up a conversation with someone I didn’t know. His response to my standard intro question — “So, what do you do?” — was “I’m a UX guy”. Based on my “smile and nod” response, I was fortunate

Read More